1. Home
  2. AIMD vs CLRB Comparison

AIMD vs CLRB Comparison

Compare AIMD & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$1.66

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Logo Cellectar Biosciences Inc.

CLRB

Cellectar Biosciences Inc.

HOLD

Current Price

$3.01

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
CLRB
Founded
1984
2002
Country
United States
United States
Employees
44
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
11.1M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AIMD
CLRB
Price
$1.66
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
22.9K
24.6K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.23
52 Week High
$4.50
$10.19

Technical Indicators

Market Signals
Indicator
AIMD
CLRB
Relative Strength Index (RSI) 57.86 56.35
Support Level $1.33 $2.50
Resistance Level $1.72 $3.44
Average True Range (ATR) 0.10 0.18
MACD 0.03 0.05
Stochastic Oscillator 63.92 95.38

Price Performance

Historical Comparison
AIMD
CLRB

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Share on Social Networks: